Brentuximab vedotin is an anticancer antibody-drug conjugate: it comprises an anti-CD30 monoclonal antibody conjugated to MMAE ( monomethyl auristatin E), a synthetic tubulin polymerisation inhibitor. The drug is given intravenously every three weeks. It has been used in treatment of relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). Excellent results were obtained in these indications. Trials are underway in combination with chemotherapy for first line treatment.

(BELG J HEMATOL 2012;4:145–149)